On January 14, following the completion of the major transaction of a RMB 1.2 billion full acquisition of Hygieia, Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), was interviewed by the globally renowned financial media outlet Bloomberg. She elaborated on the strategic significance of this acquisition and answered questions regarding future investment layout, implementation of the globalization strategy, and other topics.

On January 13, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) announced that it will fully acquire Hangzhou Hygieia Pharmaceuticals Co., Ltd. (hereinafter referred to as "Hygieia"), a domestic innovative drug company in the small interfering RNA (siRNA) field, for a total price of RMB 1.2 billion.

On December 29, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) announced that the Phase II clinical trial of TQH3906 (a TYK2/JAK1 JH2 allosteric inhibitor), a Class 1 innovative drug independently developed by CTTQ Pharma for moderate-to-severe Plaque Psoriasis (PsO), has met its primary endpoint. Study results showed that at the recommended Phase 2 dose (RP2D), after 12 weeks of treatment, the PASI 75 (Psoriasis Area and Severity Index score reduction of at least 75% from baseline) response rate exceeded 90%, and the PASI 90 (Psoriasis Area and Severity Index score reduction of at least 90% from baseline) response rate exceeded 70%.

On December 25, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) received a drug registration certificate from the National Medical Products Administration (NMPA) for the tenth indication of its Class 1 innovative drug, Anlotinib Hydrochloride Capsules.

On December 19, at the "2025 TVB Environmental, Social, and Governance (ESG) Awards Presentation Ceremony" held in Hong Kong, organized by TVB and co-organized by the Hong Kong Productivity Council, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) was honored with the "ESG Social Innovation Science and Technology Award" for its innovative practices in carbon neutrality strategy and climate risk governance.

On December 16, the "2025 Science and Technology + New Quality Productive Forces Summit", organized by the Hong Kong China Friendship Association, was held in Hong Kong.

On December 11, the world's first CDK2/4/6 inhibitor, Culmerciclib Capsules (Saitanxin®), received a drug registration approval letter from the National Medical Products Administration (NMPA).